Indian pharmaceutical firm Lupin Ltd, that entered the U.S. generic pharmaceutical market 14 years ago with the ANDA approval for Cefuroxime Axetil Tablets, has received final approval from the US FDA to market a generic version of Valeant s Ancobon capsules.
The capsules—flucytosine capsules USP (250 mg and 500mg)—are indicated for the treatment of serious infections caused by certain strains of Candida and Cryptococcus, the Indian company explained. In the US Ancobon capsules sales are worth $46.6 million ( data from March 2017 and given from Lupin)
Source: The Economic Times
